Set1/Ash2 Histone Methyltransferase Complex Subunit ASH2 (ASH2L) Peptide
ASH2L
Reactivité: Humain
Hôte: Synthetic
BP, WB
N° du produit ABIN1542425
Aperçu rapide pour Set1/Ash2 Histone Methyltransferase Complex Subunit ASH2 (ASH2L) Peptide (ABIN1542425)
Antigène
ASH2L
(Set1/Ash2 Histone Methyltransferase Complex Subunit ASH2 (ASH2L))
Origine
Humain
Source
Synthetic
Application
Blocking Peptide (BP), Western Blotting (WB)
-
-
Attributs du produit
- This is a synthetic peptide designed for use in combination with anti-ASH2L antibody (Catalog #: ARP34203_P050). It may block above mentioned antibody from binding to its target protein in western blot and/or immunohistochecmistry under proper experimental settings. There is no guarantee for its use in other applications.
-
Purification
- Purified
-
-
-
-
Indications d'application
- Each Investigator should determine their own optimal working dilution for specific applications.
-
Restrictions
- For Research Use only
-
-
-
Format
- Lyophilized
-
Reconstitution
- Add 100 μL of sterile PBS. Final peptide concentration is 1 mg/mL in PBS.
-
Concentration
- 1 mg/mL
-
Buffer
- Final peptide concentration is 1 mg/mL in PBS.
-
Conseil sur la manipulation
- Avoid repeated freeze-thaw cycles.
-
Stock
- -20 °C
-
Stockage commentaire
- For longer periods of storage, store at -20°C. Avoid repeat freeze-thaw cycles.
-
-
- ASH2L (Set1/Ash2 Histone Methyltransferase Complex Subunit ASH2 (ASH2L))
-
Sujet
-
ASH2L plays a role in hematopoiesis and is associated with some special kinds of leukemia. The amount of ASH2L transcripts is extremely high in fetal liver, testis, and leukemia cell lines with erythroid and megakaryocytic potential.
Alias Symbols: ASH2, ASH2L1, ASH2L2, Bre2
Protein Interaction Partner: DPY30,MEN1,MLL,MLL2,SMAD9,SMURF1,SMURF2,TGFBR1,UNC119,ASH2L,CHD8,CXXC1,DPY30,HCFC1,HCFC2,HIST3H3,KDM6A,MEN1,MLL,MLL3,MYB,PHF8,RBBP5,SETD1A,UNC119,WDR5,WDR82P1
Protein Size: 628 -
Poids moléculaire
- 69 kDa
-
ID gène
- 9070
-
NCBI Accession
- NM_004674, NP_004665
-
UniProt
- Q9UBL3
Antigène
-
Vous êtes ici:
